section name header

Pronunciation

droe-NED-a-rone

Classifications

Therapeutic Classification: antiarrhythmics

Pharmacologic Classification: benzofurans

Indications

BEERS REMS


Action

  • Has several antiarrhythmic properties; prolongs PR and QT intervals.
Therapeutic effects:
  • Suppression of AF.

Pharmacokinetics

Absorption: Poor bioavailability (4%) due to extensive first-pass hepatic metabolism (4%); food bioavailability (15%).

Distribution: Unknown.

Protein Binding: >98%.

Metabolism/Excretion: Undergoes extensive first-pass hepatic metabolism; mostly by the CYP3A isoenzyme. 6% excreted in urine as metabolites; 84% was excreted in feces as metabolites. Minimal elimination as unchanged drug.

Half-Life: 13–19 hr.

Time/Action Profile

(antiarrhythmic effect)

ROUTEONSETPEAKDURATION
POunknown3–6 hr12 hr



Steady state blood levels are attained at 4–8 days.

Peak levels after individual doses.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: QTc interval prolongation, HF

Derm: photosensitivity

GI: abdominal pain, diarrhea, vomiting, HEPATOTOXICITY, nausea, taste abnormality

GU: ACUTE RENAL FAILURE, renal impairment

Neuro: weakness

Resp: PNEUMONITIS, PULMONARY FIBROSIS

Misc: ANGIOEDEMA

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Multaq